These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35058323)

  • 1. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.
    Korsen JA; Kalidindi TM; Khitrov S; Samuels ZV; Chakraborty G; Gutierrez JA; Poirier JT; Rudin CM; Chen Y; Morris MJ; Pillarsetty N; Lewis JS
    J Nucl Med; 2022 Sep; 63(9):1401-1407. PubMed ID: 35058323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging with [
    Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
    Lancet Oncol; 2024 Aug; 25(8):1015-1024. PubMed ID: 38950555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
    Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human imaging with [
    Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
    medRxiv; 2024 Jan; ():. PubMed ID: 38260492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer.
    Imberti C; De Gregorio R; Korsen JA; Hoang TT; Khitrov S; Kalidindi T; Nandakumar S; Park J; Zaidi S; Pillarsetty NVK; Lewis JS
    J Nucl Med; 2024 Jul; 65(7):1043-1050. PubMed ID: 38782457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
    Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
    Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
    Wang S; Li J; Hua J; Su Y; Beckford-Vera DR; Zhao W; Jayaraman M; Huynh TL; Zhao N; Wang YH; Huang Y; Qin F; Shen S; Gioeli D; Dreicer R; Sriram R; Egusa EA; Chou J; Feng FY; Aggarwal R; Evans MJ; Seo Y; Liu B; Flavell RR; He J
    Clin Cancer Res; 2021 Mar; 27(5):1305-1315. PubMed ID: 33293372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Comparative
    Sharma SK; Adumeau P; Keinänen O; Sisodiya V; Sarvaiya H; Tchelepi R; Korsen JA; Pourat J; Edwards KJ; Ragupathi A; Hamdy O; Saunders LR; Rudin CM; Poirier JT; Lewis JS; Zeglis BM
    Bioconjug Chem; 2021 Jul; 32(7):1255-1262. PubMed ID: 33835770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
    Ruggiero A; Holland JP; Hudolin T; Shenker L; Koulova A; Bander NH; Lewis JS; Grimm J
    J Nucl Med; 2011 Oct; 52(10):1608-15. PubMed ID: 21908391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An
    Dietlein F; Kobe C; Vázquez SM; Fischer T; Endepols H; Hohberg M; Reifegerst M; Neumaier B; Schomäcker K; Drzezga AE; Dietlein M
    J Nucl Med; 2022 Apr; 63(4):573-583. PubMed ID: 34326129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer.
    Guan B; Zhou N; Wu CY; Li S; Chen YA; Debnath S; Hofstad M; Ma S; Raj GV; He D; Hsieh JT; Huang Y; Hao G; Sun X
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging of new target CDK19 in prostate cancer.
    Dai D; Yu J; Huang T; Li Y; Wang Z; Yang S; Li S; Li Y; Gou W; Li D; Hou W; Fan S; Li Y; Zhao Y
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3452-3464. PubMed ID: 37278941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiochemistry and Preclinical PET Imaging of
    Gourni E; Del Pozzo L; Bartholomä M; Kiefer Y; T Meyer P; Maecke HR; Holland JP
    Mol Imaging; 2017; 16():1536012117737010. PubMed ID: 29098927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
    J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
    Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
    BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
    Kemble J; Kwon ED; Karnes RJ
    Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
    Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.